"Trust Reinforced by Participation of Key Figures from Mayo and Duke"

DND Pharmatech announced on March 24, 2026, that its U.S.-based co-founders have exercised their stock options to increase their equity stake in the company.

DND Pharmatech company logo image. DND Pharmatech

DND Pharmatech company logo image. DND Pharmatech

View original image

This stock option exercise included overseas researchers who have been involved with the company since its early days. These individuals have been engaged in pipeline development and global strategy planning for DND Pharmatech.


Pankaj Pasricha, Chair of the Department of Medicine at Mayo Clinic in the United States, exercised his stock options in addition to all of his existing shares. These shares are subject to a lock-up period until May 2027. Philip Phan, Professor at Johns Hopkins Carey Business School, and Michael Zalutsky, Professor of Radiology at Duke University, also participated in the stock option exercise.


A DND Pharmatech representative stated, "Considering that exercising stock options incurs taxes in the United States, the co-founders’ decision to increase their equity stake can be interpreted as a reflection of their confidence in the company’s growth potential."



DND Pharmatech is currently developing a range of treatments, including the MASH therapy 'DD01', obesity treatments, and therapies for degenerative brain diseases. The company is also advancing both global clinical trials and commercialization efforts in parallel.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing